Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats

MLA

Takafumi Matsumoto, et al. “Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats.” Journal of Pharmacological Sciences, vol. 107, no. 3, Jan. 2008, pp. 340–48. EBSCOhost, https://doi.org/10.1254/jphs.08071FP.

APA

Takafumi Matsumoto, Yoshiyuki Ono, Akemi Kuromiya, Kaoru Toyosawa, Yoshinaka Ueda, & Vera Bril. (2008). Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats. Journal of Pharmacological Sciences, 107(3), 340–348. https://doi.org/10.1254/jphs.08071FP

Chicago

Takafumi Matsumoto, Yoshiyuki Ono, Akemi Kuromiya, Kaoru Toyosawa, Yoshinaka Ueda, and Vera Bril. 2008. “Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats.” Journal of Pharmacological Sciences 107 (3): 340–48. doi:10.1254/jphs.08071FP.